Study: Aspirin Early On Could Be Effective For COVID Patients

Aspirin may reduce the risk of death in hospitalized COVID patients with moderate symptoms, according to a study by George Washington University. The study found a 1.6% reduction in death risk, especially benefiting older patients with underlying conditions. Aspirin is globally accessible and affordable, unlike more expensive treatments like monoclonal antibodies. However, federal funding cuts are affecting the availability of such treatments. Non-hospitalized COVID patients should consult doctors before taking aspirin.

What impact did the reduction in federal funding have on monoclonal antibody treatments?

What caution is advised for individuals who are home sick with COVID-19 regarding aspirin?